EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Agios Pharmaceuticals's Enterprise Value is €1,851.55 Mil.
Agios Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-339.38 Mil. Therefore, Agios Pharmaceuticals's EV-to-FCF for today is -5.46.
The historical rank and industry rank for Agios Pharmaceuticals's EV-to-FCF or its related term are showing as below:
STU:8AP'
s EV-to-FCF Range Over the Past 10 Years
Min: -83.65 Med: -5.06 Max: 62.39
Current: -5.34
During the past 13 years, the highest EV-to-FCF of Agios Pharmaceuticals was 62.39. The lowest was -83.65. And the median was -5.06.
STU:8AP's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs STU:8AP: -5.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Agios Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Agios Pharmaceuticals's share price for today is €32.40.
Agios Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.232.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Agios Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's EV-to-FCF falls into.
Agios Pharmaceuticals's current Enterprise Value is €1,851.55 Mil.
Agios Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-339.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (STU:8AP) has a EV-to-FCF of -5.46 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Agios Pharmaceuticals and its competitors. According to the industry distribution chart, Agios Pharmaceuticals ranks #999999 out of 333 companies in the Biotechnology industry.
Is Agios Pharmaceuticals' EV-to-FCF too high?
Agios Pharmaceuticals' current EV-to-FCF is -5.46. Based on the distribution chart, Agios Pharmaceuticals ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Agios Pharmaceuticals has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' EV-to-FCF compare to ABCL and KOD?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #999999 out of 333 companies for EV-to-FCF. This places Agios Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 15.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Agios Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agios Pharmaceuticals's current EV-to-FCF is -5.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (STU:8AP) is currently considered Possible Value Trap. The stock's GF Value™ is €73.52, compared to a current price of €32.40 — trading 55.9% below its estimated fair value. The current EV-to-FCF is -5.46. Agios Pharmaceuticals' overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Agios Pharmaceuticals (STU:8AP), the current EV-to-FCF is -5.46 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (STU:8AP) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of €32.40 is trading 55.9% below its estimated GF Value™ of €73.52.
GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.
Key valuation signals for STU:8AP:
EV-to-FCF: -5.46
GF Value™: €73.52 vs. price of €32.40 (55.9% below fair value)
No single metric tells the full story. See the STU:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
48GF Score
Get the complete analysis for STU:8AP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:8AP has been successfully added to your 
